Evotec and Plectonic form research alliance to advance next‑generation T‑cell‑engaging bispecifics for solid‑tumor immunotherapy
Executive summary: Evotec and Plectonic entered a research collaboration to validate Evotec's BiTco costimulatory CD2 bispecifics platform in combination with Plectonic's LOGIBODY® technology for solid‑tumor immunotherapy. The partnership seeks to enhance T‑cell activation through costimulatory signaling, potentially improving the efficacy of immunotherapy against solid tumors and broadening Evotec's oncology pipeline.
Who is involved: Evotec (a Germany‑based biotechnology company) and Plectonic (developer of the LOGIBODY® DNA‑protein immunotherapy platform).
Likely next: The collaborators will proceed with pre‑clinical validation, and any results will be disclosed in subsequent updates.
Evotec announced a collaboration with Plectonic to test its BiTco costimulatory CD2 bispecific platform together with Plectonic's LOGIBODY® DNA‑protein immunotherapy. The work focuses on solid tumors, aiming to boost T‑cell activation via a costimulatory signaling pathway. No financial terms or timelines were disclosed in the release.
Timeline
- — Evotec and Plectonic Enter Research Collaboration to Explore New Generation of T-Cell-Engaging Approaches for Solid Tumors (PR Newswire)